Does Rallies show Form 4 insider transactions for PMN?

Yes. Rallies tracks PMN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is PMN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PMN. It does not provide personalized investment advice.

PMN (ProMIS Neurosciences Inc. Common Shares (ON)) Stock Analysis - Insider Trades

ProMIS Neurosciences Inc. Common Shares (ON) (PMN) is a publicly traded Healthcare sector company. As of May 21, 2026, PMN trades at $10.75 with a market cap of $93.58M and a P/E ratio of -0.47. PMN moved +0.00% today. Year to date, PMN is +43.24%; over the trailing twelve months it is -19.24%. Its 52-week range spans $6.27 to $39.75. Analyst consensus is buy with an average price target of $35.00. Rallies surfaces PMN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading PMN stock inside the company?

Recent PMN insider activity includes Kirwin Patrick D. bought 4.00K, Williams Eugene bought 2.00K, Williams Eugene bought 2.00K, Williams Eugene bought 1.00K, and Williams Eugene bought 1.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

PMN Key Metrics

Key financial metrics for PMN
Metric	Value
Price	$10.75
Market Cap	$93.58M
P/E Ratio	-0.47
EPS	$-22.61
Dividend Yield	0.00%
52-Week High	$39.75
52-Week Low	$6.27
Volume	12
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-39.72M
Gross Margin	0.00%

Recent PMN Insider Trades

Kirwin Patrick D. bought 4.00K (~$45.32K) on Apr 22, 2026.
Williams Eugene bought 2.00K (~$48.80K) on Mar 5, 2026.
Williams Eugene bought 2.00K (~$48.00K) on Mar 4, 2026.
Williams Eugene bought 1.00K (~$21.89K) on Mar 3, 2026.
Williams Eugene bought 1.00K (~$22.53K) on Mar 2, 2026.

Latest PMN News

ProMIS Neurosciences Secures $175M PIPE Financing, Funds Fully Enrolled Phase 1b Trial — May 12, 2026
ProMIS Neurosciences to Present at Conference, Details Mid-2026 Interim Analysis for PRECISE-AD — Apr 13, 2026
ProMIS to Present Two Vaccine Posters Targeting ALS, Parkinson’s at AD/PD 2026 — Mar 18, 2026

PMN Analyst Consensus

1 analysts cover PMN: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $35.00.

Common questions about PMN

Who is trading PMN stock inside the company?: Recent PMN insider activity includes Kirwin Patrick D. bought 4.00K, Williams Eugene bought 2.00K, Williams Eugene bought 2.00K, Williams Eugene bought 1.00K, and Williams Eugene bought 1.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for PMN?: Yes. Rallies tracks PMN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is PMN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PMN. It does not provide personalized investment advice.